Colorado Chromatography Labs, LLC

A review.Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries.A background on the discovery, synthesis, and pharmacol. studies of hydrogenated and saturated cannabinoids is described.This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids.A discussion of structure-activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review.According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo.However, the effects of HHC treatment have not been studied in humans, and thus a biol. profile has not been established.

Despite recent advances in chemotherapy, pancreatic cancer remains a deadly disease and is the third leading cause of cancer related death in the United States and by 2030, it will be second only to lung cancer.This is remarkable as it has Orphan Drug Designation, as there are approx. 56,000 new cases of pancreatic cancer diagnosed each year in the United States (2019, per the NCI).However, there are about 46,000 patient deaths, a disturbing fatality rate.Clin. studies on the utility of cannabinoids in the treatment of pancreatic cancer are lacking and urgently needed.With only small incremental gains, and a growing specificity of target (and therefore smaller patient target groups, some of whom may ultimately develop resistance), there is an urgent unmet need for broader, better and less toxic treatments for pancreatic cancer.Our group aims to exploit a remarkable property of a modified derivatives of rare cannabinoids, exemplified by CCL-104, that selectively disrupts the replication of cancer cells.Disrupted replication leads to cell death, while allowing healthy cells to proliferate normally.These effects are predominately mediated through, but not limited to cannabinoid receptor-1 (CB1), cannabinoid receptor-2 (CB2), and G-protein-coupled receptor 55 (GPCR55) pathways'.

Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancers, this type of epithelial lung cancer has various subtypes including squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.NSCLC are usually less sensitive to chemotherapy and radiation, while treatments can keep the cancer from spreading, and local resectable cancers can be cured, most NSCLC un-resectable cases, have no cures.As lung cancer is the leading cause of cancer-related mortality in the United States, novel treatments are pertinent to combating the disease.CCL Analogs synthesized from natural products were tested through in-vitro screening to generate IC50 values of analogs towards the treatment of epithelial lung cancers.Several CCL compounds were tested with cell viability decreasing at modest concentrations compared to antineoplastics (gemcitabine, paclitaxel, 5-FU) at similar concentrationsXenograft data was conducted with CCL compounds with the lead compound exhibiting 36% in tumor reduction mass.Ongoing research is being conducted to optimize and provide better reduction leading to more successful treatment in NSCLC.